JP2010527375A5 - - Google Patents

Download PDF

Info

Publication number
JP2010527375A5
JP2010527375A5 JP2010508596A JP2010508596A JP2010527375A5 JP 2010527375 A5 JP2010527375 A5 JP 2010527375A5 JP 2010508596 A JP2010508596 A JP 2010508596A JP 2010508596 A JP2010508596 A JP 2010508596A JP 2010527375 A5 JP2010527375 A5 JP 2010527375A5
Authority
JP
Japan
Prior art keywords
gpr12
long
term memory
memory formation
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010508596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010527375A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/063804 external-priority patent/WO2008144453A1/en
Publication of JP2010527375A publication Critical patent/JP2010527375A/ja
Publication of JP2010527375A5 publication Critical patent/JP2010527375A5/ja
Pending legal-status Critical Current

Links

JP2010508596A 2007-05-15 2008-05-15 Ｇｐｒ１２の阻害による認知障害の治療方法 Pending JP2010527375A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93816307P 2007-05-15 2007-05-15
PCT/US2008/063804 WO2008144453A1 (en) 2007-05-15 2008-05-15 Methods of treating cognitive disorders by inhibition of gpr12

Publications (2)

Publication Number Publication Date
JP2010527375A JP2010527375A (ja) 2010-08-12
JP2010527375A5 true JP2010527375A5 (enExample) 2011-06-23

Family

ID=40122145

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010508596A Pending JP2010527375A (ja) 2007-05-15 2008-05-15 Ｇｐｒ１２の阻害による認知障害の治療方法

Country Status (11)

Country Link
US (2) US7968524B2 (enExample)
EP (1) EP2162137B1 (enExample)
JP (1) JP2010527375A (enExample)
KR (1) KR20100029079A (enExample)
CN (1) CN101808647A (enExample)
AU (1) AU2008254905A1 (enExample)
BR (1) BRPI0811625A2 (enExample)
CA (1) CA2684920A1 (enExample)
IL (1) IL202091A0 (enExample)
MX (1) MX2009012316A (enExample)
WO (1) WO2008144453A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2595720C2 (ru) 2009-04-09 2016-08-27 Когнишн Терапьютикс, Инк. Ингибиторы снижения когнитивных способностей
US9192585B2 (en) 2009-07-31 2015-11-24 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
WO2011106785A2 (en) * 2010-02-26 2011-09-01 Cognition Therapeutics, Inc. Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
RU2013140467A (ru) 2011-02-02 2015-03-10 Когнишн Терапьютикс, Инк. Выделенные соединения из масла куркумы и способы применения
AU2015210852B2 (en) 2014-01-31 2019-01-24 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
DK3634394T3 (da) 2017-05-15 2026-03-02 Cognition Therapeutics Inc Sammensætninger til behandling af neurogenerative sygdomme
BR102022009685A2 (pt) * 2022-05-18 2023-11-28 Fundação Oswaldo Cruz Método para triagem de fármacos ou substâncias com potencial neuroprotetor, kit para triagem de fármacos ou substâncias, e, uso de um painel de genes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6045094A (en) 1993-02-19 1994-09-14 Nippon Shinyaku Co. Ltd. Drug composition containing nucleic acid copolymer
US6291438B1 (en) 1993-02-24 2001-09-18 Jui H. Wang Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
US5858988A (en) 1993-02-24 1999-01-12 Wang; Jui H. Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
EP0755454B1 (en) 1994-04-13 2008-02-13 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US6653086B1 (en) * 1998-04-14 2003-11-25 Arena Pharmaceuticals, Inc. Endogenous constitutively activated G protein-coupled orphan receptors
WO2001048483A2 (en) * 1999-12-10 2001-07-05 Astrazeneca Ab Method for screening of appetite control agents
US20040224316A1 (en) * 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
US20060247194A1 (en) 2000-08-30 2006-11-02 Sirna Therapeutics , Inc. Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
KR100872437B1 (ko) * 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US6586524B2 (en) 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
US20040023384A1 (en) * 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of G protein-coupled receptor 12 expression
US20050106731A1 (en) 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
WO2004014933A1 (en) 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
WO2004038407A2 (en) * 2002-10-24 2004-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
US7829694B2 (en) * 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
EP1662862A1 (en) * 2003-09-19 2006-06-07 Paradigm Therapeutics Limited Receptor
SI1745295T1 (sl) * 2004-04-20 2011-01-31 Galapagos Nv Metode, sestavljanje in preizkuĺ anje spojine za zaviranje tvorbe proteina amiloid-beta

Similar Documents

Publication Publication Date Title
Jeong et al. Activation of temperature-sensitive TRPV1-like receptors in ARC POMC neurons reduces food intake
Davis et al. Ghrelin signaling affects feeding behavior, metabolism, and memory through the vagus nerve
Ng et al. Indoxyl sulfate downregulates expression of Mas receptor via OAT3/AhR/Stat3 pathway in proximal tubular cells
Meyer et al. A ghrelin–growth hormone axis drives stress-induced vulnerability to enhanced fear
Lan et al. Deficiency of NOX1 or NOX4 prevents liver inflammation and fibrosis in mice through inhibition of hepatic stellate cell activation
Kilduff et al. Activation of cortical interneurons during sleep: an anatomical link to homeostatic sleep regulation?
Crossland et al. Focal adhesion kinase is required for IGF-I-mediated growth of skeletal muscle cells via a TSC2/mTOR/S6K1-associated pathway
Troca-Marín et al. An increase in basal BDNF provokes hyperactivation of the Akt-mammalian target of rapamycin pathway and deregulation of local dendritic translation in a mouse model of Down's syndrome
Thomas et al. Adolescent nicotine exposure alters GABAA receptor signaling in the ventral tegmental area and increases adult ethanol self-administration
Ren et al. Neuropeptide S: a novel regulator of pain-related amygdala plasticity and behaviors
Moaddab et al. Oxytocin receptor neurotransmission in the dorsolateral bed nucleus of the stria terminalis facilitates the acquisition of cued fear in the fear-potentiated startle paradigm in rats
Aceto et al. Chronic mild stress alters synaptic plasticity in the nucleus accumbens through GSK3β-dependent modulation of Kv4. 2 channels
Forsberg et al. CO2-evoked release of PGE2 modulates sighs and inspiration as demonstrated in brainstem organotypic culture
Munari et al. Selective brain region activation by histamine H3 receptor antagonist/inverse agonist ABT-239 enhances acetylcholine and histamine release and increases c-Fos expression
John et al. Caffeine promotes glutamate and histamine release in the posterior hypothalamus
WO2010093872A3 (en) Molecular-based method of cancer diagnosis and prognosis
Roberts et al. Dopamine release in nucleus accumbens is under tonic inhibition by adenosine A1 receptors regulated by astrocytic ENT1 and dysregulated by ethanol
Sane et al. The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain
Li et al. The paraventricular thalamus mediates visceral pain and anxiety-like behaviors via two distinct pathways
Fricke et al. Glutamine uptake by System A transporters maintains neurotransmitter GABA synthesis and inhibitory synaptic transmission
UA116871C2 (uk) СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
Tanaka et al. Antihyperalgesic effects of ProTx-II, a Nav1. 7 antagonist, and A803467, a Nav1. 8 antagonist, in diabetic mice
Xing et al. Acid‐sensing ion channel subtype 3 function and immunolabelling increases in skeletal muscle sensory neurons following femoral artery occlusion
Li et al. Experimental colitis modulates the functional properties of NMDA receptors in dorsal root ganglia neurons
Bancroft et al. Extracellular S100B inhibits A‐type voltage‐gated potassium currents and increases L‐type voltage‐gated calcium channel activity in dopaminergic neurons